Quantcast

Latest Glioma Stories

2014-07-02 16:24:28

In this phase two study, 50 percent of glioblastoma patients lived for two years, an encouraging result for one of the most deadly cancers that often kills patients within one year of diagnosis CHICAGO, July 2, 2014 /PRNewswire-USNewswire/ -- Patients newly diagnosed with glioblastoma multiforme (GBM) and treated with an experimental cancer vaccine made from the patient's own tumor in addition to standard of care lived longer compared to those who received standard of care alone,...

2014-06-27 14:56:01

German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) A clinical phase I trial to examine the safety of the vaccine against gliomas based on mutant IDH1 in human patients is planned Astrocytomas and oligodendrogliomas are subtypes of a brain cancer called 'glioma'. These incurable brain tumors arise from glial cells, a type of support cell found in the central nervous system. "Low-grade gliomas", which grow comparatively slowly, spread in a diffuse manner across the...

2014-06-27 12:26:56

HOUSTON, June 27, 2014 /PRNewswire/ -- The Burzynski Research Institute, Inc. (BRI) announced today that it will present data on two of the Company's clinical-stage product candidates, Antineoplaston A10 injections (Atengenal(®)) and Antineoplaston AS2-1 injections (Astugenal(®)), at the 16(th) International Symposium on Pediatric Neuro-Oncology held in Singapore from June 28, 2014 to July 2, 2014. Abstracts and presentations are now available to the public in an online supplement...

2014-06-24 08:31:08

U.S. Phase 2a Clinical Trial in Recurrent Glioblastoma to Initiate in Early 2015 SYDNEY, June 24, 2014 /PRNewswire/ -- EnGeneIC, Ltd., an emerging biopharmaceutical company focused on revolutionizing the treatment of cancer through the targeted delivery of therapeutic agents directly to cancer cells, today announced plans to move forward with a Phase 2a clinical trial in the U.S. using its formulation of EGFR-targeted, EDV(TM) nanocells packaged with doxorubicin for the treatment...

2014-06-17 11:02:54

Ohio State University Giving low doses of a particular targeted agent with a cancer-killing virus might improve the effectiveness of the virus as a treatment for cancer, according to a study led by researchers with The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James). Viruses that are designed to kill cancer cells – oncolytic viruses – have shown promise in clinical trials for the...

2014-06-17 08:29:17

SAN DIEGO, June 17, 2014 /PRNewswire/ -- DNAtrix, Inc., experts in oncolytic virus development, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track status for its lead product, DNX-2401, a replication competent adenovirus, for patients with recurrent gliobastoma. The FDA gives Fast Track status to facilitate the development of new products for serious or life-threatening conditions which demonstrate the potential to address unmet medical needs,...

2014-06-13 08:23:58

Analysis of PRiDe, a U.S. commercial registry of 457 recurrent glioblastoma patients, demonstrates that patients treated with NovoTTF Therapy at their first recurrence achieved a median overall survival of 20 months NEW YORK, June 13, 2014 /PRNewswire/ -- Novocure, a commercial stage oncology company, announced today that subgroup survival data from its U.S. commercial patient registry will be presented at the 16(th) Biennial Canadian Neuro-Oncology Meeting in Halifax, Nova Scotia,...

2014-06-10 12:31:14

LONDON, June 10, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Recurrent Malignant Glioma - Pipeline Review, H1 2014http://www.reportbuyer.com/pharma_healthcare/diseases/recurrent_malignant_glioma_pipeline_review_h1_2013.html Recurrent Malignant Glioma - Pipeline Review, H1 2014SummaryGlobal Markets Direct's, 'Recurrent Malignant Glioma - Pipeline Review, H1 2014', provides an overview of the Recurrent Malignant Glioma's therapeutic pipeline.This report...

2014-06-09 14:11:57

University of California - San Francisco A double-edged sword, gene variants may promote overall health while increasing risk of gliomas New genomic research led by UC San Francisco (UCSF) scientists reveals that two common gene variants that lead to longer telomeres, the caps on chromosome ends thought by many scientists to confer health by protecting cells from aging, also significantly increase the risk of developing the deadly brain cancers known as gliomas. The genetic...

2014-06-03 13:06:47

Duke University Medical Center A collaborative effort between Duke Medicine researchers and neurosurgeons and scientists in China has produced new genetic insights into a rare and deadly form of childhood and young adult brain cancer called brainstem glioma. The researchers identified a genetic mutation in the tumor cells that plays a role in both the growth and the death of a cell. Additionally, the mutation to the newly identified gene may also contribute to the tumor's resistance to...


Word of the Day
omphalos
  • The navel or umbilicus.
  • In Greek archaeology: A central boss, as on a shield, a bowl, etc.
  • A sacred stone in the temple of Apollo at Delphi, believed by the Greeks to mark the 'navel' or exact center-point of the earth.
'Omphalos' comes from the ancient Greek.
Related